Advertisement

Clinical Research in Cardiology

, Volume 108, Issue 2, pp 203–211 | Cite as

Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life

  • Tarek BekfaniEmail author
  • Pierpaolo Pellicori
  • Daniel Morris
  • Nicole Ebner
  • Miroslava Valentova
  • Anja Sandek
  • Wolfram Doehner
  • John G. Cleland
  • Mitja Lainscak
  • P. Christian Schulze
  • Stefan D. Anker
  • Stephan von Haehling
Original Paper
  • 275 Downloads

Abstract

Background

The prevalence of iron deficiency (ID) in outpatients with heart failure with preserved ejection fraction (HFpEF) and its relation to exercise capacity and quality of life (QoL) is unknown.

Methods

190 symptomatic outpatients with HFpEF (LVEF 58 ± 7%; age 71 ± 9 years; NYHA 2.4 ± 0.5; BMI 31 ± 6 kg/m2) were enrolled as part of SICA-HF in Germany, England and Slovenia. ID was defined as ferritin < 100 or 100–299 µg/L with transferrin saturation (TSAT) < 20%. Anemia was defined as Hb < 13 g/dL in men, < 12 g/dL in women. Low ferritin-ID was defined as ferritin < 100 µg/L. Patients were divided into 3 groups according to E/e′ at echocardiography: E/e′ ≤ 8; E/e′ 9–14; E/e′ ≥ 15. All patients underwent echocardiography, cardiopulmonary exercise test (CPX), 6-min walk test (6-MWT), and QoL assessment using the EQ5D questionnaire.

Results

Overall, 111 patients (58.4%) showed ID with 89 having low ferritin-ID (46.84%). 78 (41.1%) patients had isolated ID without anemia and 54 patients showed anemia (28.4%). ID was more prevalent in patients with more severe diastolic dysfunction: E/e′ ≤ 8: 44.8% vs. E/e′: 9–14: 53.2% vs. E/e′ ≥ 15: 86.5% (p = 0.0004). Patients with ID performed worse during the 6MWT (420 ± 137 vs. 344 ± 124 m; p = 0.008) and had worse exercise time in CPX (645 ± 168 vs. 538 ± 178 s, p = 0.03). Patients with low ferritin-ID had lower QoL compared to those without ID (p = 0.03).

Conclusion

ID is a frequent co-morbidity in HFpEF and is associated with reduced exercise capacity and QoL. Its prevalence increases with increasing severity of diastolic dysfunction.

Keywords

Heart failure with preserved ejection fraction Iron deficiency Exercise capacity Quality of life 

Abbreviations

ANOVA

Analysis of variance

ATP

Adenosine triphosphate

BMI

Body mass index

CPX

Cardiopulmonary exercise test

DEXA

Dual energy X-ray absorptiometry

HB

Hemoglobin

HF

Heart failure

HFpEF

Heart failure with preserved ejection fraction

HFrEF

Heart failure with reduced ejection fraction

ID

Iron deficiency

LAVI

Left atrial volume index

LV

Left ventricular

6-MWT

6-min walk test

NYHA

New York Heart Association

QoL

Quality of life

SD

Standard deviation

SICA-HF

Studies investigating co-morbidities aggravating heart failure

TSAT

Transferrin saturation

Notes

Funding

The study was funded by the European Commission’s 7th Framework program (FP7/2007–2013) under grant agreement number 241558 (clinical.trial.gov).

Compliance with ethical standards

Conflict of interest

SvH is consulting and has received honoraria for speaking from Solartium Dietetics, Professional Dietetics, Vifor, Novartis, Respicardia, Sorin, and Pfizer. SDA is consulting, has received honoraria for speaking and/or attended advisory boards for Amgen Inc, Professional Dietetics, Psioxus Therapeutics, GTx, Helsinn, GSK, Sanofi, Regeneron, Novartis, Takeda, Servier, Chugai and Vifor. All other authors report no conflict of interest.

References

  1. 1.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259CrossRefGoogle Scholar
  2. 2.
    Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW (2011) Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 58:265–274CrossRefGoogle Scholar
  3. 3.
    Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA (2006) Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114:2138–2147CrossRefGoogle Scholar
  4. 4.
    Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM (2010) Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56:845–854CrossRefGoogle Scholar
  5. 5.
    Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD (2011) Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 13:1296–1304CrossRefGoogle Scholar
  6. 6.
    Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM (2010) Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 56:855–863CrossRefGoogle Scholar
  7. 7.
    Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, Wong K, Zhang J, Cleland JG, Clark AL (2014) Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Cardiovasc Imaging 30:69–79CrossRefGoogle Scholar
  8. 8.
    Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ (1991) Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 17:1065–1072CrossRefGoogle Scholar
  9. 9.
    von Haehling S, van Veldhuisen DJ, Roughton M, Babalis D, de Boer RA, Coats AJS, Manzano L, Flather M, Anker S (2011) D. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 13:656–663CrossRefGoogle Scholar
  10. 10.
    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448CrossRefGoogle Scholar
  11. 11.
    Clark AL, Poole-Wilson PA, Coats AJ (1996) Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 28:1092–1102CrossRefGoogle Scholar
  12. 12.
    Massie BM, Conway M, Rajagopalan B, Yonge R, Frostick S, Ledingham J, Sleight P, Radda G (1988) Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure: evidence for abnormalities unrelated to blood flow. Circulation 78:320–326CrossRefGoogle Scholar
  13. 13.
    Dunn LL, Rahmanto YS, Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol 17:93–100CrossRefGoogle Scholar
  14. 14.
    Fairbanks V, Beutler E (2001) Iron deficiency. In: Beutler E (ed) Williams hematology, 6th edn. McGraw-Hill, New York, pp 295–304 (447–70).Google Scholar
  15. 15.
    von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol.  https://doi.org/10.1038/nrcardio.2015.109 Google Scholar
  16. 16.
    Andrews NC, Schmidt P (2007) J.Iron homeostasis. Annu Rev Physiol 69:69–85CrossRefGoogle Scholar
  17. 17.
    Haas JD, Brownlie TIV (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131(Suppl 2):676–688CrossRefGoogle Scholar
  18. 18.
    Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD (2016) Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Fail 3(3):145–151CrossRefGoogle Scholar
  19. 19.
    Yeo TJ, Yeo PS, Hadi FA, Cushway T, Lee KY, Tai BC, Lam CS (2016) Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF). ESC Heart Fail 3(2):71–76CrossRefGoogle Scholar
  20. 20.
    Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E (2017) Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: the IRONOUT HF randomized clinical trial. JAMA 19:1958–1966CrossRefGoogle Scholar
  21. 21.
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh Th, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD (2015). on behalf of for the CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36:657–668CrossRefGoogle Scholar
  22. 22.
    Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165:575–582CrossRefGoogle Scholar
  23. 23.
    Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relations to anemia, exercise capacity, and survival. J Am Coll Cardiol 58:1241–1251CrossRefGoogle Scholar
  24. 24.
    Kasner M, Aleksandrov AS, Westermann D, Lassner D, Gross M, von Haehling S, Anker SD, Schultheiss HP, Tschöpe C (2013) Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Int J Cardiol 168:4652–4657CrossRefGoogle Scholar
  25. 25.
    Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880CrossRefGoogle Scholar
  26. 26.
    von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, Rozentryt P, Rauchhaus M, Karpov R, Tkachuk V, Parfyonova Y, Zaritskey AY, Shlyakhto EV, Cleland JG, Anker SD (2010) Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle 1:187–194CrossRefGoogle Scholar
  27. 27.
    Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefGoogle Scholar
  28. 28.
    Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193CrossRefGoogle Scholar
  29. 29.
    Bruce RA, Blackmon JR, Jones JW, Strait G (1963) Exercise testing in adult normal subjects and cardiac patients. Pediatrics 32:742–756Google Scholar
  30. 30.
    Naughton J, Sevellus G, Balke B (1963) Physiologic responses of normal and pathologic subjects to a modified work capacity test. J Sports Med 31:201Google Scholar
  31. 31.
    Krack A, Sharma R, Figulla HR, Anker SD (2005) The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26:2368–2374CrossRefGoogle Scholar
  32. 32.
    Silverberg DS (2011) The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev 16:609–614CrossRefGoogle Scholar
  33. 33.
    Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023CrossRefGoogle Scholar
  34. 34.
    Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50:1561–1569CrossRefGoogle Scholar
  35. 35.
    Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352(10):1011–1023CrossRefGoogle Scholar
  36. 36.
    Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M (2009) Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 54:402–409CrossRefGoogle Scholar
  37. 37.
    Anker SD, Colet JC, Filippatos G et al (2009) Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11:1084–1091CrossRefGoogle Scholar
  38. 38.
    van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8:485–493CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Tarek Bekfani
    • 1
    • 2
    Email author
  • Pierpaolo Pellicori
    • 3
  • Daniel Morris
    • 1
  • Nicole Ebner
    • 4
  • Miroslava Valentova
    • 4
    • 5
  • Anja Sandek
    • 4
  • Wolfram Doehner
    • 1
    • 6
  • John G. Cleland
    • 3
  • Mitja Lainscak
    • 7
  • P. Christian Schulze
    • 2
  • Stefan D. Anker
    • 8
    • 9
  • Stephan von Haehling
    • 1
    • 4
  1. 1.Department of Cardiology, Campus Virchow-KlinikumCharité Medical SchoolBerlinGermany
  2. 2.Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, Department of Internal Medicine I, University Hospital JenaFriedrich-Schiller-UniversityJenaGermany
  3. 3.Department of CardiologyUniversity of HullHullUK
  4. 4.Department of Cardiology and PneumologyUniversity of Göttingen Medical CenterGöttingenGermany
  5. 5.Department of Internal MedicineComenius UniversityBratislavaSlovakia
  6. 6.Center for Stroke Research BerlinCharité Medical SchoolBerlinGermany
  7. 7.Department of CardiologyGolnik UniversityGolnikSlovenia
  8. 8.Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, Campus Virchow-KlinikumCharité Medical SchoolBerlinGermany
  9. 9.Berlin-Brandenburg Center for Regenerative Therapies (BCRT)Charité Medical School BerlinBerlinGermany

Personalised recommendations